---
title: "Liminatus Pharma files late notice for quarterly report for June 30, 2025"
url: "https://aibio.space/news/liminatus-pharma-files-late-notice-quarterly-report-june-30-2025/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-08-15"
section: "Distress"
tickers: "NASDAQ:LIMN"
source: "https://www.sec.gov/Archives/edgar/data/1971387/000110465925078852/tm2516820d2_nt10q.htm"
summary: "The company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace"
---

By the aibio.space news desk.

Sources

- [Liminatus Pharma, Inc. NT 10-Q (2025-08-15)](https://www.sec.gov/Archives/edgar/data/1971387/000110465925078852/tm2516820d2_nt10q.htm)

[LIMN](https://aibio.space/companies/liminatus-pharma/)

2025-08-15

# Liminatus Pharma files late notice for quarterly report for June 30, 2025

Tickers [LIMN](https://aibio.space/companies/liminatus-pharma/)

The company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace period.

## Key facts

- **Company**: Liminatus Pharma, Inc. (NASDAQ: LIMN)

- **News type**: Distress

- **Primary source**: [Liminatus Pharma, Inc. NT 10-Q (2025-08-15)](https://www.sec.gov/Archives/edgar/data/1971387/000110465925078852/tm2516820d2_nt10q.htm)

*The facade of a neoclassical court building at dusk. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Liminatus Pharma, Inc. told the Securities and Exchange Commission that it could not file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 on time.

The company made the disclosure on Form 12b-25, a notice of late filing. A company uses this form when it misses a report deadline. Filing it gives the company a short extra period. For a quarterly report, that period runs to the fifth calendar day after the original due date.

Liminatus said it could not file on time "because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the subject report and signatures thereto in a timely fashion prior to the due date of the report."

The company checked the box stating that the quarterly report will be filed on or before the fifth calendar day after the due date.

Liminatus said it has filed all other periodic reports required during the preceding 12 months. It also said it does not expect a significant change in results of operations from the same period of the last fiscal year to be reflected in the report.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

LIMN

Liminatus Pharma, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/liminatus-pharma-files-late-notice-quarterly-report-june-30-2025/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Liminatus Pharma files late notice for quarterly report for June 30, 2025", 2025-08-15, https://aibio.space/news/liminatus-pharma-files-late-notice-quarterly-report-june-30-2025/